One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Body, Soul, and Hypnotherapy
Ehud Mekori-Domachevsky, Shomron Ben-Horin
doi : 10.1093/ecco-jcc/jjaa266
Journal of Crohn's and Colitis, Volume 15, Issue 7, July 2021, Pages 1083–1084
Patient-Reported Outcomes in Inflammatory Bowel Diseases: Another Piece in the Puzzle
S Restellini, P L Lakatos
doi : 10.1093/ecco-jcc/jjaa261
Journal of Crohn's and Colitis, Volume 15, Issue 7, July 2021, Pages 1085–1086
Tofacitinib De-escalation Strategy in Ulcerative Colitis: Is It the End of the Story?
Lucas Guillo, Laurent Peyrin-Biroulet, Edouard Louis
doi : 10.1093/ecco-jcc/jjab006
Journal of Crohn's and Colitis, Volume 15, Issue 7, July 2021, Pages 1087–1088
ECCO Topical Review Optimising Reporting in Surgery, Endoscopy, and Histopathology: Collaboration Between S-ECCO, EduCom, H-ECCO
Michel Adamina, Roger Feakins, Marietta Iacucci, Antonino Spinelli, Rosanna Cannatelli, André D’Hoore, Ann Driessen, Konstantinos Katsanos, Aart Mookhoek, P?r Myrelid, Gianluca Pellino, Georgios Peros, Gian Eugenio Tontini, Monika Tripathi, Henit Yanai, Magali Svrcek
doi : 10.1093/ecco-jcc/jjab011
Journal of Crohn's and Colitis, Volume 15, Issue 7, July 2021, Pages 1089–1105
Diagnosis and management of inflammatory bowel diseases [IBD] requires a lifelong multidisciplinary approach. The quality of medical reporting is crucial in this context. The present topical review addresses the need for optimised reporting in endoscopy, surgery, and histopathology.
Hypnotherapy for Irritable Bowel Syndrome-Type Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Controlled Trial
Daniël R Hoekman, Arine M Vlieger, Pieter C Stokkers, Nofel Mahhmod, Svend Rietdijk, Nanne K de Boer, Tim G de Meij, Carla Frankenhuis, Geert R D’Haens, Marc A Benninga
doi : 10.1093/ecco-jcc/jjaa241
Journal of Crohn's and Colitis, Volume 15, Issue 7, July 2021, Pages 1106–1113
Many inflammatory bowel disease [IBD] patients in remission have persisting symptoms, compatible with irritable bowel syndrome [IBS-type symptoms]. We aimed to compare the effectiveness of gut-directed hypnotherapy vs standard medical treatment [SMT] for IBS-type symptoms in IBD patients.
End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn’s Disease
Emily C L Wong, Elisa Buffone, So Jeong Lee, Parambir S Dulai, John K Marshall, Walter Reinisch, Neeraj Narula
doi : 10.1093/ecco-jcc/jjaa242
Journal of Crohn's and Colitis, Volume 15, Issue 7, July 2021, Pages 1114–1119
It is unclear whether early symptom improvement in Crohn’s disease [CD] provides any prognostic information for patients long-term. This paper aims to investigate the relationship between early patient-reported outcomes [PROs] after completion of induction of infliximab, and their relationship with long-term clinical remission [CR] and endoscopic remission [ER].
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study
William J Sandborn, Brian G Feagan, Stephen Hanauer, Severine Vermeire, Subrata Ghosh, Wenzhong J Liu, AnnKatrin Petersen, Lorna Charles, Vivian Huang, Keith Usiskin, Douglas C Wolf, Geert D’Haens
doi : 10.1093/ecco-jcc/jjab012
Journal of Crohn's and Colitis, Volume 15, Issue 7, July 2021, Pages 1120–1129
This analysis examined the long-term safety and efficacy of ozanimod in patients with moderately to severely active ulcerative colitis [UC] with ??4 years of follow-up in the phase 2 TOUCHSTONE open-label extension [OLE].
Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial
Séverine Vermeire, Chinyu Su, Nervin Lawendy, Taku Kobayashi, William J Sandborn, David T Rubin, Irene Modesto, Sean Gardiner, Nicole Kulisek, Haiying Zhang, Wenjin Wang, Julian Panés
doi : 10.1093/ecco-jcc/jjaa249
Journal of Crohn's and Colitis, Volume 15, Issue 7, July 2021, Pages 1130–1141
Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We present primary completion analysis from RIVETING, an ongoing, double-blind, randomised, parallel-group trial evaluating efficacy and safety of tofacitinib dose reduction to 5 mg twice daily [BID] versus remaining on 10 mg BID in patients in stable remission on tofacitinib 10 mg BID maintenance therapy.
Hypoalbuminaemia, Not Biologic Exposure, Is Associated with Postoperative Complications in Crohn’s Disease Patients Undergoing Ileocolic Resection
Ravi S Shah, Salam Bachour, Xue Jia, Stefan D Holubar, Tracy L Hull, Jean-Paul Achkar, Jessica Philpott, Taha Qazi, Florian Rieder, Benjamin L Cohen, Miguel D Regueiro, Amy L Lightner, Benjamin H Click
doi : 10.1093/ecco-jcc/jjaa268
Journal of Crohn's and Colitis, Volume 15, Issue 7, July 2021, Pages 1142–1151
There are limited data on the postoperative outcomes in Crohn’s disease patients exposed to preoperative ustekinumab or vedolizumab. We hypothesised that preoperative biologic use in Crohn’s disease is not associated with postoperative complications after ileocolic resection.
Ability of Pelvic Magnetic Resonance Imaging to Predict Clinical Course of Perianal Fistula in Paediatric Crohn’s Disease Patients
Pyeong Hwa Kim, Seo Hee Kim, Young Ah Cho, Hee Mang Yoon, Jin Seong Lee, Ah Young Jung, Seak Hee Oh, Dae Yeon Kim, Jung-Man Namgoong, Kyung Mo Kim
doi : 10.1093/ecco-jcc/jjab004
Journal of Crohn's and Colitis, Volume 15, Issue 7, July 2021, Pages 1152–1160
Evidence is limited regarding clinical course and magnetic resonance imaging [MRI] features of perianal fistula [PAF] in Korean children with Crohn’s disease [CD]. We investigated MRI features of PAF and associations with long-term outcomes.
Degree of Creeping Fat Assessed by Computed Tomography Enterography is Associated with Intestinal Fibrotic Stricture in Patients with Crohn’s Disease: A Potentially Novel Mesenteric Creeping Fat Index
Xue-Hua Li, Shi-Ting Feng, Qing-Hua Cao, J Calvin Coffey, Mark E Baker, Li Huang, Zhuang-Nian Fang, Yun Qiu, Bao-Lan Lu, Zhi-Hui Chen, Yi Li, Dominik Bettenworth, Marietta Iacucci, Can-Hui Sun, Subrata Ghosh, Florian Rieder, Min-Hu Chen, Zi-Ping Li, Ren Mao
doi : 10.1093/ecco-jcc/jjab005
Journal of Crohn's and Colitis, Volume 15, Issue 7, July 2021, Pages 1161–1173
Emerging evidence points to a link between creeping fat and the pathogenesis of Crohn’s disease [CD]. Non-invasive assessment of the severity of creeping fat on cross-sectional imaging modality has seldom been investigated. This study aimed to develop and characterize a novel mesenteric creeping fat index [MCFI] based on computed tomography [CT] in CD patients.
Course of Disease in Patients with Microscopic Colitis: A European Prospective Incident Cohort Study
Bas P M Verhaegh, Andreas Münch, Danila Guagnozzi, Signe Wildt, Wojciech Cebula, Andreea R Diac, Fernando Fern?ndez-Ba?ares, Magid A R Al-Khalaf, Natalia Pedersen, Juozas Kupcinskas, Johan Bohr, Gilles Macaigne, Alfredo J Lucendo, Ivan Lyutakov, Gian-Eugenio Tontini, Flavia Pig?, Evangelos Russo, Henrik Hjortswang, Stephan Miehlke, Lars K Munck
doi : 10.1093/ecco-jcc/jjab007
Journal of Crohn's and Colitis, Volume 15, Issue 7, July 2021, Pages 1174–1183
The disease course of microscopic colitis [MC] is considered chronic but benign. However, this assumption is based on mainly retrospective studies, reporting on incomplete follow-up of selective cohorts. Systematic, prospective and unbiased data to inform patients and healthcare professionals on the expected course of the disease and real-life response to therapy are warranted.
Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis
Brigida Barberio, Jonathan P Segal, M Nabil Quraishi, Christopher J Black, Edoardo V Savarino, Alexander C Ford
doi : 10.1093/ecco-jcc/jjab010
Journal of Crohn's and Colitis, Volume 15, Issue 7, July 2021, Pages 1184–1196
5-Aminosalicylates [5-ASAs] are the mainstay of treatment for ulcerative colitis [UC]. The optimum preparation, dose, and route of administration for UC remain unclear. We conducted a network meta-analysis to examine this issue.
Modulation of the Gut Microbiota-farnesoid X Receptor Axis Improves Deoxycholic Acid-induced Intestinal Inflammation in Mice
Mengque Xu, Yuqin Shen, Mengsha Cen, Yubin Zhu, Fangli Cheng, Linlin Tang, Xia Zheng, John J Kim, Ning Dai, Weiling Hu
doi : 10.1093/ecco-jcc/jjab003
Journal of Crohn's and Colitis, Volume 15, Issue 7, July 2021, Pages 1197–1210
Inflammatory bowel disease (IBD) is associated with gut dysbiosis and dysregulation of bile acid metabolism. A high luminal content of deoxycholic acid (DCA) with consumption of a Westernised diet is implicated in the pathogenesis of IBD. The aim of the study is to explore the role of intestinal microbiota and bile acid metabolism in mice with DCA-induced intestinal inflammation.
Predicting Outcome in Acute Severe Colitis—Controversies in Clinical Practice in 2021
Vipin Gupta, Waled Mohsen, Thomas P Chapman, Jack Satsangi
doi : 10.1093/ecco-jcc/jjaa265
Journal of Crohn's and Colitis, Volume 15, Issue 7, July 2021, Pages 1211–1221
Acute severe ulcerative colitis [ASUC] remains a common medical emergency, with 25% of patients with ulcerative colitis experiencing at least one event in their disease course. Despite advances in medical therapy, ASUC continues to be associated with considerable morbidity and mortality, with up to 30% of patients requiring colectomy during initial admission. Our aim was to review the current controversies and recent progress in risk stratification, prediction of outcome, and personalisation of care in ASUC. We re-assess the use of Truelove and Witts’ criteria, serum biomarkers, and the use of composite clinical indices in current clinical practice. We explore the potential for endoscopic prediction using defined validated indices for accurate and early prognostication, and the need to define outcome. We also consider the impact of the current COVID-19 pandemic. Finally, we discuss the current research agenda, including the application of new and emerging biomarkers coupled with multi-omics and the implications in management and optimisation of outcome. Research priorities for the prediction of outcome in acute severe colitis include the following.
Organoid-based Models to Study the Role of Host-microbiota Interactions in IBD
Martina Poletti, Kaline Arnauts, Marc Ferrante, Tamas Korcsmaros
doi : 10.1093/ecco-jcc/jjaa257
Journal of Crohn's and Colitis, Volume 15, Issue 7, July 2021, Pages 1222–1235
The gut microbiota appears to play a central role in health, and alterations in the gut microbiota are observed in both forms of inflammatory bowel disease [IBD], namely Crohn’s disease and ulcerative colitis. Yet, the mechanisms behind host-microbiota interactions in IBD, especially at the intestinal epithelial cell level, are not yet fully understood. Dissecting the role of host-microbiota interactions in disease onset and progression is pivotal, and requires representative models mimicking the gastrointestinal ecosystem, including the intestinal epithelium, the gut microbiota, and immune cells. New advancements in organoid microfluidics technology are facilitating the study of IBD-related microbial-epithelial cross-talk, and the discovery of novel microbial therapies. Here, we review different organoid-based ex vivo models that are currently available, and benchmark their suitability and limitations for specific research questions. Organoid applications, such as patient-derived organoid biobanks for microbial screening and ’omics technologies, are discussed, highlighting their potential to gain better mechanistic insights into disease mechanisms and eventually allow personalised medicine.
Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review
Lucas Guillo, Ferdinando D’Amico, Silvio Danese, Laurent Peyrin-Biroulet
doi : 10.1093/ecco-jcc/jjaa260
Journal of Crohn's and Colitis, Volume 15, Issue 7, July 2021, Pages 1236–1243
Extra-intestinal manifestations [EIMs] are frequent in patients with inflammatory bowel diseases [IBD] and are challenging conditions to manage. Tumour necrosis factor alpha antagonists [anti-TNF?] are recognised as the primary therapeutic option. We aimed to summarise evidence on the efficacy of ustekinumab for the treatment of EIMs.
Recurrent COVID-19 in a Patient With Ulcerative Colitis on Vedolizumab Therapy
Femke Crouwel, Petra Waaijenberg-Warmenhoven, Hans J C Buiter, Nanne K de Boer
doi : 10.1093/ecco-jcc/jjaa259
Journal of Crohn's and Colitis, Volume 15, Issue 7, July 2021, Pages 1244–1245
Association Between Statin Use and Inflammatory Bowel Diseases
Cong Dai, Min Jiang, Yu-hong Huang
doi : 10.1093/ecco-jcc/jjaa258
Journal of Crohn's and Colitis, Volume 15, Issue 7, July 2021, Page 1246
